1-6 of 6
Elizabeth L. Budde
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 3771–3772.
https://doi.org/10.1182/blood-2022-157710
Published: 2022
Journal Articles

Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Steven I. Park, Stephen M. Ansell, Sharmila Giri, Jakub Svoboda, Stephen D Smith, Tatyana Feldman, Elizabeth L. Budde, Andrew J Ness, Yunsik Choi, Philip J Bierman, Hun Ju Lee
Journal: Blood
Blood (2022) 140 (Supplement 1): 1751–1752.
https://doi.org/10.1182/blood-2022-159258
Published: 2022
Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung-Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutierrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Hess, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn
Journal: Blood
Blood (2022) 140 (Supplement 1): 3753–3755.
https://doi.org/10.1182/blood-2022-157729
Published: 2022
Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Robert Stuver, Laure Michaud, Carla Casulo, Ranjana H. Advani, Elizabeth L. Budde, Paul M. Barr, Connie Lee Batlevi, Philip C Caron, Louis S. Constine, Savita Dandapani, Pamela Drullinsky, Jonathan W. Friedberg, Clare Grieve, Audrey Hamilton, Paul A. Hamlin, Richard Hoppe, Steven M. Horwitz, Niloufer Khan, Matthew J. Matasar, Ariela Noy, M.Lia Palomba, Heiko Schoder, David J. Straus, Shreya Vemuri, Joachim Yahalom, Joanna C. Yang, Anas Younes, Andrew D. Zelenetz, Craig H. Moskowitz, Anita Kumar, Alison J. Moskowitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 1756–1758.
https://doi.org/10.1182/blood-2022-156382
Published: 2022
Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Genevive H. Hernandez, John So, Kathryn A. Logronio, Maya F. Kotturi, Won Seog Kim, Philippe Armand, Chan Y. Cheah, Ajay K. Gopal, Ian W. Flinn, Gareth P. Gregory, Matthew J. Matasar, Loretta J. Nastoupil, Catherine S. Diefenbach, Sung-Soo Yoon, Matthew Ku, Ibrahim Qazi, Maya K. Leabman, Iris Sison, Bruce A. Keyt, Chris H. Takimoto, Thomas J. Manley, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 6436–6438.
https://doi.org/10.1182/blood-2022-163235
Published: 2022
Journal Articles

Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Vaibhav Agrawal, Cindy Croslin, Asuscena L. Beltran, Jianying Zhang, Joycelynne Palmer, Quy Huynh-Tran, Rochelle Hernandez, Sandra Thomas, Marjorie Robbins, Ahmed Aribi, Haris Ali, Anthony S. Stein, Elizabeth L. Budde, Monzr M. Al Malki, Guido Marcucci
Journal: Blood
Blood (2022) 140 (Supplement 1): 6235–6236.
https://doi.org/10.1182/blood-2022-165894
Published: 2022